Neurogene Inc.
NGNE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NGNE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NGNE
Neurogene Inc. (NGNE) is a clinical-stage gene therapy company focused on developing treatments for rare neurological diseases, with a lead candidate in Phase 3 trials and an in-house manufacturing facility, but has no approved products and faces significant capital needs.
Key risk: No approved products
BioSniper Score
Based on 6 of 6 signals
Market Cap
$732.0M
Cash Runway
27.9 moLead Asset
ngn-101 (Phase 3)
Next Catalyst
Phase3_Topline · Dec 1, 2029Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials · 1 catalyst for Neurogene Inc..
Neurogene Inc. (NGNE) is a clinical-stage gene therapy company focused on developing treatments for rare neurological diseases, with a lead candidate in Phase 3 trials and an in-house manufacturing facility, but has no approved products and faces significant capital needs.
- Neurogene has no products approved for commercial sale and has not generated any commercial revenue from product sales [sec_mda · as of 2026-08-11].
- As of 2026-06-30, the company reported cash & equivalents of $112.8M, a net loss of -$34.5M, shareholders' equity of $264.9M, and no debt [sec].
- The company's cash and short-term investments are expected to fund operations into the second half of 2027, though this estimate may change [sec · filed 2024-12-02].
- Neurogene has an in-house cGMP manufacturing facility in Houston, Texas, which it believes provides control over quality, timelines, and financial flexibility [sec_mda · as of 2025-11-13].
- The company discontinued its NGN-101 gene therapy program for CLN5 Batten disease in November 2024 after an RMAT application was denied [sec_mda · as of 2025-11-13].
What works
- Neurogene has an in-house cGMP manufacturing facility that enables control over product quality, development timelines, and clinical-to-commercial continuity [sec_mda · as of 2025-11-13].
- The company is participating in the FDA's START and RMAT programs for its NGN-401 clinical trial, which may provide regulatory support [sec · filed 2024-12-02].
- As of 2026-06-30, the company has no debt and $112.8M in cash, providing a runway into the second half of 2027 [sec].
What to weigh
- Neurogene has no approved products and has never generated commercial revenue; profitability, if ever, is expected to take many years [sec_mda · as of 2026-08-11].
- The company has incurred significant operating losses and negative cash flows, and expects expenses to increase substantially [sec_mda · as of 2026-05-12].
- Additional capital will be needed to fund operations, and there is no assurance that such capital will be available on acceptable terms [sec_mda · as of 2026-08-11].
- The NGN-101 program for CLN5 Batten disease was discontinued after an RMAT application was denied, highlighting regulatory and development risks [sec_mda · as of 2025-11-13].
From the filings
Quoted directly from source documents.
No approved products or commercial revenue
“We do not have any products approved for commercial sale and have not generated any commercial revenue from product sales.”
SEC MD&A · August 11, 2026
Discontinuation of NGN-101 program
“in November 2024 we decided not to move forward with the NGN-101 gene therapy program for CLN5 Batten disease, given the rarity of the disease and the lack of a streamlined registrational pathway with the FDA following denial of our RMAT application for that program”
SEC MD&A · November 13, 2025
In-house manufacturing facility
“We also established a fully operational current good manufacturing practices (" cGMP") facility in Houston, Texas used to manufacture current and future product for research, toxicology and clinical studies.”
SEC MD&A · November 13, 2025
Catalyst timeline
- 2029-12-01 · Phase3_Topline — Phase 3 Topline: A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy — Topline results from the pivotal Phase 3 study will be a key determinant of the lead candidate's regulatory path and commercial potential.
Risks & what to watch (4)›
Key risks
- No approved products — No products approved for commercial sale; no commercial revenue generated; profitability expected to take many years [sec_mda · as of 2026-08-11].
- Capital needs and dilution — Requires substantial additional capital; no assurance of raising capital on acceptable terms; may need to reduce operations [sec_mda · as of 2026-08-11].
- Clinical and regulatory setbacks — NGN-101 program discontinued after RMAT denial; other programs may face similar delays or failures [sec_mda · as of 2025-11-13].
- Operating losses and cash burn — Significant operating losses and negative cash flows; expenses expected to increase substantially [sec_mda · as of 2026-05-12].
What to watch
- Phase 3 topline data for the lead gene therapy candidate, expected around 2029-12-01 [upcoming catalysts].
- Progress of NGN-401 clinical trial under FDA's START and RMAT programs [sec · filed 2024-12-02].
- Ability to raise additional capital and manage cash runway beyond the second half of 2027 [sec · filed 2024-12-02].
- Any updates on pipeline programs following the discontinuation of NGN-101 [sec_mda · as of 2025-11-13].
Sources: SEC filings · SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run Neurogene Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Neurogene Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
27.9 months
D/E 0.13 · 0% dilution
Lead: Phase 3
2 candidates
1 upcoming, next in ~1189d
0 buys · 16 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
94
Total value held
$258.7M
| Holder | Shares | Value |
|---|---|---|
| samsara biocapital, llc | 1,717,127 | $34.6M |
| rtw investments, lp | 1,362,456 | $27.5M |
| vanguard capital management llc | 1,029,454 | $20.8M |
| blackrock, inc. | 1,005,070 | $20.3M |
| baker bros. advisors lp | 991,691 | $20.0M |
| balyasny asset management l.p. | 718,389 | $14.5M |
| toronto dominion bank | 681,337 | $13.7M |
| jennison associates llc | 527,685 | $10.6M |
| arrowmark colorado holdings llc | 524,796 | $10.6M |
| great point partners llc | 500,000 | $10.1M |
Showing top 10 of 94 institutional holders of Neurogene Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 29.8%
- Days to cover
- 22.6
- Shares short
- 3,720,441
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NGNE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Neurogene Inc.?
Neurogene Inc. (NGNE) is a clinical-stage gene therapy company focused on developing treatments for rare neurological diseases, with a lead candidate in Phase 3 trials and an in-house manufacturing facility, but has no approved products and faces significant capital needs.
What is Neurogene Inc.'s lead drug candidate?
Neurogene Inc.'s most advanced tracked candidate is ngn-101 (Phase 3) for CLN5 Batten disease.
What is Neurogene Inc.'s next catalyst?
Neurogene Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy, " — expected December 1, 2029.
Who is the CEO of Neurogene Inc.?
Dr. Rachel L. McMinn Ph.D. is the chief executive officer of Neurogene Inc. (NGNE).
Where is Neurogene Inc. headquartered?
Neurogene Inc. (NGNE) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.